Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN (QGEN) to Enhance Forensics With New Partnership

by Zacks Equity Research

QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.

Zacks Equity Research

International Markets and Qiagen (QGEN): A Deep Dive for Investors

by Zacks Equity Research

Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Equity Research

QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.

Zacks Equity Research

Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Qiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 4.55% and 0.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Qiagen (QGEN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches

by Zacks Equity Research

QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.

Zacks Equity Research

QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access

by Zacks Equity Research

With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.

Zacks Equity Research

QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness

by Zacks Equity Research

QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.

Zacks Equity Research

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

by Zacks Equity Research

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.